$GANXr/pennystocksGeneral Discussionbullish u/Keeg117 · 240d agono track record yet Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17.
Gain Therapeutics is developing the first drug to reverse Parkinson's disease, backed by human data showing 81% reduction in brain toxins and significant physical recovery in 90 days. With a $100M market cap and major catalysts on 3/17–18, analysts project 400%+ upside with potential for multi-billion dollar buyout.
At post $2.51·Now $1.13-55.0% since postedas of Oct 30, 4:45 PM ET
1d+21.5%
3d+21.5%
1w+9.6%
1m-26.3%
3m-28.7%
6m-29.5%
1y—
Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s?
Gain Therapeutics' lead drug GT-02287 has demonstrated statistically significant UPDRS improvement in Parkinson's patients and is expected to present neuron repair and DDC biomarker data at the AD/PD conference on 3/18/26, potentially validating the first disease-modifying drug to reverse Parkinson's. With a market cap around $125M and cash runway through end of year, the company is likely a takeover target for big pharma partners valuing Parkinson's assets at billions.
At post $2.57·Now $1.13-56.0% since postedas of Oct 30, 4:45 PM ET
1d-2.3%
3d+18.7%
1w+10.5%
1m-28.0%
3m-28.8%
6m-30.0%
1y—
($GANX): March Update- Evidence of Disease Modification Keeps Getting Stronger
Gain Therapeutics has demonstrated statistically significant UPDRS functional improvement and correlated biomarker evidence (GluSph reduction and DDC normalization) showing disease modification in Parkinson's disease. The company will present additional evidence at the AD/PD conference on 3/17, and with strong institutional ownership growth and elevated short interest, an acquisition or partnership appears likely.
At post $2.71·Now $1.13-58.3% since postedas of Oct 30, 4:45 PM ET
1d-3.0%
3d-7.4%
1w+8.1%
1m-28.4%
3m-28.0%
6m-34.7%
1y—
$GANX- CEO interview just came out-- dispels any misconceptions
GANX's CEO interview reveals the company has achieved disease-modifying evidence for Parkinson's through their GluSph biomarker, which was a pre-specified FDA endpoint showing reduction in glutathione depletion and improvement in UPDRS scores. The author believes the recent sell-off was an overreaction and that GANX's drug will be the first disease-modifying treatment for Parkinson's, making it an attractive entry point at a discount.
At post $2.88·Now $1.13-60.7% since postedas of Oct 30, 4:45 PM ET
1d—
3d+11.0%
1w+9.6%
1m-37.0%
3m-33.9%
6m-38.1%
1y—
"Lightning in a Bottle": "Groundbreaking Early Readout For Gain Therapeutics Gives It A Shot At First Disease-Modifying Drug For Parkinson’s" $GANX
Gain Therapeutics' GT-02287 represents a potential multi-billion-dollar breakthrough for Parkinson's disease, addressing up to 90% of the patient population through a novel mechanism. With analyst price targets of $18-$34 per share, strong preclinical/early clinical data, and likely acquisition interest from major pharma (following recent large biotech partnerships), the stock is significantly undervalued at current single-digit levels ahead of imminent data release.
At post $3.95·Now $1.13-71.4% since postedas of Oct 30, 4:45 PM ET
1d-2.3%
3d-43.0%
1w-19.2%
1m-44.3%
3m-38.5%
6m-57.5%
1y—
$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)
Gain Therapeutics' GT-02287 shows consistent, positive clinical progress with strong phase 1b biomarker improvements and patient/clinician enthusiasm suggesting potential for the first truly disease-modifying Parkinson's drug. CEO's confident public statements, upcoming data readout within days, and asymmetric risk/reward (especially for GBA1 subgroup) suggest significant overnight upside similar to recent biotech catalysts, with minimal downside.
At post $4.11·Now $1.13-72.5% since postedas of Oct 30, 4:45 PM ET
1d+0.7%
3d+0.7%
1w-45.3%
1m-43.8%
3m-30.9%
6m-59.9%
1y—
Inflammation: The Common Denominator in Parkinson's Disease ($GANX)
GT-02287, an allosteric GCase modulator developed by Gain Therapeutics, targets the self-amplifying inflammation-mitochondria-lysosome doom loop in Parkinson's disease by restoring mitochondrial energy and lysosomal clearance. Phase 1 data shows target engagement, CNS exposure, mitochondrial/lysosomal rescue, and directional improvements in UPDRS over 90 days, positioning it as a potential disease-modifying therapy rather than merely symptomatic relief.
At post $3.99·Now $1.13-71.7% since postedas of Oct 30, 4:45 PM ET
1d—
3d+4.8%
1w+3.8%
1m-36.1%
3m-23.6%
6m-57.4%
1y—
$GANX be careful guys!
The company's mitochondria-first Parkinson's thesis lacks rigor, relying on N=1 data with statistically insignificant improvements. Placebo effects in Parkinson's trials are notoriously strong (20-30%), and the sector graveyard is full of promising preclinical candidates that failed in blinded trials, including Sanofi's Venglustat and antibodies from Roche and Biogen.
At post $3.99·Now $1.13-71.7% since postedas of Oct 30, 4:45 PM ET
1d—
3d+1.5%
1w+3.8%
1m-25.6%
3m-23.6%
6m-53.4%
1y—
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Phase 1b trial data shows GT-02287 achieved statistically significant UPDRS score improvement in Parkinson's patients within 90 days, unprecedented for a short trial duration. With a small market cap relative to Parkinson's market size and upcoming full data readout expected to confirm the effect across all 16 patients, the stock has significant upside potential if the drug represents a true disease-modifying breakthrough.
At post $3.50·Now $1.13-67.7% since postedas of Oct 30, 4:45 PM ET
1d+10.0%
3d+10.0%
1w+17.4%
1m-9.1%
3m-26.6%
6m-47.7%
1y—
Gain Therapeutics($GANX) has returned Smell to Parkinson's patients in 2025 and has major catalysts before year end
Gain Therapeutics' GT-02287 has demonstrated disease-modifying effects in Parkinson's trials, including restoration of smell and UPDRS improvements in just 90 days. Multiple catalysts before year-end (additional patient data, biomarker results, FDA IND submission) combined with high trial demand suggest significant upside potential and a likely acquisition by big pharma.
At post $2.83·Now $1.13-60.1% since postedas of Oct 30, 4:45 PM ET
1d+3.2%
3d+11.0%
1w+14.5%
1m+13.8%
3m-31.4%
6m-37.1%
1y—
Parkinson's Drug On Verge Of Historical Data Release (likely acquired at 10X or more in coming month)s: GANX
Gain Therapeutics' Parkinson's drug GT-02287 appears poised for a major biomarker data release in 4–5 weeks that could confirm disease modification and trigger acquisition interest. With a sub-$100M market cap, even a modest $1B+ acquisition would deliver 10x+ returns, making this a high-asymmetry setup.
At post $2.95·Now $1.13-61.7% since postedas of Oct 30, 4:45 PM ET
1d+1.4%
3d-4.1%
1w-6.8%
1m+40.3%
3m-39.7%
6m-38.3%
1y—
This $2 biotech might cure Parkinson’s and save Medicare billions. (Ticker: $GANX)
GANX, a $70M microcap, is developing a potential disease-modifying Parkinson's therapy showing early clinical success. Biomarker data due in 4–6 weeks could confirm blood–brain barrier penetration, α-synuclein reduction, and GCase activation; a successful readout or partnership announcement could trigger acquisition-level valuations ($1–$2B) or strategic deals, driving stock to $10–$15/share.
At post $2.49·Now $1.13-54.6% since postedas of Oct 30, 4:45 PM ET
1d—
3d+18.5%
1w+13.7%
1m+62.7%
3m-29.7%
6m-26.9%
1y—